The global Burn and Scald Medicine market size is predicted to grow from US$ 4641 million in 2025 to US$ 6286 million in 2031; it is expected to grow at a CAGR of 5.2% from 2025 to 2031.

Burn and scald medicine refers to a kind of medicine used to treat skin and tissue damage caused by heat, chemical substances, electric shock or radiation. These drugs are designed to reduce pain, prevent infection, promote wound healing, and minimize scar formation, focusing on the most commonly used burn wound dressings and topical drugs in adults and children.

United States market for Burn and Scald Medicine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Burn and Scald Medicine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Burn and Scald Medicine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Burn and Scald Medicine players cover Nipro, MediWound, STADA Arzneimittel, Elastoplast, Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Burn and Scald Medicine Industry Forecast” looks at past sales and reviews total world Burn and Scald Medicine sales in 2024, providing a comprehensive analysis by region and market sector of projected Burn and Scald Medicine sales for 2025 through 2031. With Burn and Scald Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Burn and Scald Medicine industry.

This Insight Report provides a comprehensive analysis of the global Burn and Scald Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Burn and Scald Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Burn and Scald Medicine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Burn and Scald Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Burn and Scald Medicine.

This report presents a comprehensive overview, market shares, and growth opportunities of Burn and Scald Medicine market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Dressing
    Ointment
    Spray

Segmentation by Application:

    Hospital
    Clinic
    Pharmacy
    Online

This report also splits the market by region:

    Americas

        United States
        Canada
        Mexico
        Brazil

    APAC

        China
        Japan
        Korea
        Southeast Asia
        India
        Australia

    Europe

        Germany
        France
        UK
        Italy
        Russia

    Middle East & Africa

        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    Nipro
    MediWound
    STADA Arzneimittel
    Elastoplast
    Pfizer
    Bharat Biotech
    Paul Hartmann
    Ono Pharmaceutical
    Centaur Pharmaceuticals
    Kedrion Biopharma
    Smith & Nephew
    ConvaTec
    B. Braun Melsungen
    Coloplast
    Mölnlycke Health Care
    Medline Industries
    Hartmann
    Ferndale Pharmaceuticals
    Guizhou Jingcheng Medicine
    Mebo Pharmaceutical Technology
    Shanghai Tenry Pharm
    Guilin Huanuo Gene Pharmaceutical
    Shanghai Haohai Biotechnology
    Beijing SL Pharmaceutical
    Hubei Mayinglong Pharmaceutical
    Jianmin Group
    Tianjin Pharm Group
    Cardinal Health
    Integra LifeSciences
    Deroyal
    DermaRite Industries